Kyverna Therapeutics, Inc. (KYTX)
NASDAQ:KYTX
KYTX Stock Chart & Stats
$7.80
-$0.14(-3.63%)
At close: 4:00 PM EST
$7.80
-$0.14(-3.63%)
Day’s Range― - ―
52-Week Range$1.78 - $13.67
Previous CloseN/A
Volume87.17K
Average Volume (3M)591.23K
Market Cap
$458.13M
Enterprise Value$236.88M
Total Cash (Recent Filing)$279.25M
Total Debt (Recent Filing)$29.03M
Price to Earnings (P/E)―
Beta1.69
Next Earnings
May 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.80
Shares Outstanding60,439,890
10 Day Avg. Volume660,765
30 Day Avg. Volume591,231
Financial Highlights & Ratios
PEG Ratio-0.28
Price to Book (P/B)1.79
Price to Sales (P/S)0.00
P/FCF Ratio-2.71
Enterprise Value/Market Cap0.52
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-131.67
Enterprise Value/Ebitda-1.47
Forecast
1Y Price Target
$27.67Price Target Upside254.74% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-3.28
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Balance Sheet & Cash RunwayLow financial leverage and substantial assets give Kyverna durable financing flexibility to fund late-stage development and initial commercialization activities. A multi-year cash runway into 2028 reduces near-term refinancing pressure, enabling focus on BLA filing, manufacturing scale-up, and regulatory milestones rather than immediate capital raises.
Experienced Board & Management HiresAdding executives with proven drug development, commercialization and capital-markets experience strengthens governance and execution capability. These hires materially improve regulatory, clinical and commercialization know-how for CAR-T programs, reducing execution risk around filings and launch planning over the next several quarters.
Advancing Toward Commercialization & Clinical ProgressProgress to a planned BLA and active Phase 3 enrollment signal clinical de-risking and path to first-in-class commercialization in autoimmune CAR-T. Sustained clinical momentum and IND acceptance support a scalable franchise opportunity and meaningful long-term revenue potential if regulatory approvals and launches succeed.
Bears Say
No Revenue And Widening LossesThe absence of recent revenue and rapidly widening net losses reflect heavy R&D and operating investment without commercialization. Persistently negative profitability undermines return metrics and forces reliance on external funding; absent successful approvals, this structural loss profile threatens long-term shareholder value.
Accelerating Cash Burn And Negative Cash FlowOperating and free cash flow have deteriorated materially, increasing the cadence of funding needs. Even with a multi-year runway, accelerating burn restricts ability to invest concurrently in commercial scale-up and additional indications without new capital, elevating execution risk and the likelihood of future dilution.
Reliance On Equity Financing And Potential DilutionThe company’s use of inducement equity, expanded share pools and recent shelf/offerings signals a structural reliance on equity to fund operations. Persistent equity-based financing and large option grants increase long-term share count pressure, which can dilute returns and complicate capital allocation as commercialization begins.
Kyverna Therapeutics, Inc. News
KYTX FAQ
What was Kyverna Therapeutics, Inc.’s price range in the past 12 months?
Kyverna Therapeutics, Inc. lowest stock price was $1.78 and its highest was $13.67 in the past 12 months.
What is Kyverna Therapeutics, Inc.’s market cap?
Kyverna Therapeutics, Inc.’s market cap is $458.13M.
When is Kyverna Therapeutics, Inc.’s upcoming earnings report date?
Kyverna Therapeutics, Inc.’s upcoming earnings report date is May 19, 2026 which is in 48 days.
How were Kyverna Therapeutics, Inc.’s earnings last quarter?
Kyverna Therapeutics, Inc. released its earnings results on Mar 26, 2026. The company reported -$0.8 earnings per share for the quarter, beating the consensus estimate of -$0.851 by $0.051.
Is Kyverna Therapeutics, Inc. overvalued?
According to Wall Street analysts Kyverna Therapeutics, Inc.’s price is currently Undervalued.
Does Kyverna Therapeutics, Inc. pay dividends?
Kyverna Therapeutics, Inc. does not currently pay dividends.
What is Kyverna Therapeutics, Inc.’s EPS estimate?
Kyverna Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kyverna Therapeutics, Inc. have?
Kyverna Therapeutics, Inc. has 60,439,890 shares outstanding.
What happened to Kyverna Therapeutics, Inc.’s price movement after its last earnings report?
Kyverna Therapeutics, Inc. reported an EPS of -$0.8 in its last earnings report, beating expectations of -$0.851. Following the earnings report the stock price went down -2.864%.
Which hedge fund is a major shareholder of Kyverna Therapeutics, Inc.?
Currently, no hedge funds are holding shares in KYTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kyverna Therapeutics, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$27.67 (254.74% Upside)
$27.67 (254.74% Upside)
Blogger Sentiment
Bullish
KYTX Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 2.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days >0.1%
Last 30 Days ▲ 0.7%
Last 30 Days ▲ 0.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
231.21%
12-Months-Change
Fundamentals
Return on Equity
-81.41%
Trailing 12-Months
Asset Growth
-3.77%
Trailing 12-Months
Company Description
Kyverna Therapeutics, Inc.
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
KYTX Stock 12 Month Forecast
Average Price Target
$27.67
▲(254.74% Upside)
Technical Analysis
Codexis
―
Heron Therapeutics
―
Silence Therapeutics
―
Atea Pharmaceuticals
―
Entrada Therapeutics Inc
―
Ownership Overview
24.67% Insiders
6.08% Mutual Funds
40.41% Other Institutional Investors
24.73% Public Companies and Individual Investors